Friday, 28 March, 12.15-13.45, Gold Hall
A MULTICENTRE, RANDOMISED, PHASE 3 TRIAL OF A NOVEL, AUTOLOGOUS, THERAPEUTIC VACCINE (VITESPEN) VS. OBSERVATION AS ADJUVANT THERAPY IN PATIENTS AT HIGH RISK OF RECURRENCE AFTER NEPHRECTOMY FOR RENAL CELL CARCINOMA